Cell & Gene Therapy - End To End Services

Moving a cell or gene therapy toward commercialization means aligning process design, manufacturing, analytics and regulatory strategy before problems surface at tech transfer or filing. This end-to-end model is built around that alignment, spanning autologous and allogeneic cell therapy, viral vectors, in vivo applications and extracellular vesicles.

It follows four connected capabilities: process development with cGMP considerations from the outset, clinical and commercial manufacturing, phase-appropriate bioassay transfer into GMP quality control, and dedicated CMC regulatory support from IND/IMPD through post-approval variations. It also points to the combined lentiviral vector and RNA/LNP expertise behind in vivo CAR-T and gene-editing programs, along with the scale and site footprint of the CDMO behind the services.

Explore the capabilities to see how each stage connects to the next.